Percutaneous hepatic perfusion

Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

Retrieved on: 
Monday, May 9, 2022
ASCO, Department, Percutaneous hepatic perfusion, Nasdaq, GLOBE, H. Lee Moffitt Cancer Center & Research Institute, Delcath Systems, Chair, Poster, Patient, Mother, American Society of Clinical Oncology, FDA, FOCUS, Medicine, Mum, PHP, Society, Sale, Liver, Region, Melphalan, Annual general meeting, Pharmaceutical industry

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held in-person on June 3-7, 2022, in Chicago, Illinois.

Key Points: 
  • NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held in-person on June 3-7, 2022, in Chicago, Illinois.
  • Title: FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A)
    Presenter: Dr. Jonathan Zager, Director of Regional Therapies and Chief Academic Officer, Moffitt Cancer Center; Professor and Chair, Department of Oncologic Sciences, USF Morsani School of Medicine
    The poster will be available at https://delcath.com/investors/events-presentations/ when the ASCO embargo is released on May 26, 2022, at 4:00 PM CDT.
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

Retrieved on: 
Wednesday, July 28, 2021
Medical specialties, Clinical medicine, Medicine, Hepatology, Cancer treatments, Cancer, Oncology, Delcath Systems, Percutaneous hepatic perfusion, Interventional oncology, Liver cancer, Chemotherapy

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.

Key Points: 
  • NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.
  • To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
  • The call will also be available over the Internet and accessible at:
    Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems Announces a KOL Call on November 5, 2020 to discuss the Results of a Prospective Phase II Study in Patients with Metastatic Ocular Melanoma

Retrieved on: 
Thursday, October 29, 2020
Medical specialties, Medicine, Clinical medicine, Hepatology, Specialty drugs, Delcath Systems, Melanoma, Percutaneous hepatic perfusion, Metastatic liver disease, Uveal melanoma, Interventional radiology, Melphalan

Dr. Mark Burgmans will discuss results from a prospective phase II study conducted atLeiden University Medical Center on the use of the Delcath CHEMOSATHepatic Delivery System with Melphalan (CHEMOSAT) to treat patients with metastatic ocular melanoma with liver metastases.

Key Points: 
  • Dr. Mark Burgmans will discuss results from a prospective phase II study conducted atLeiden University Medical Center on the use of the Delcath CHEMOSATHepatic Delivery System with Melphalan (CHEMOSAT) to treat patients with metastatic ocular melanoma with liver metastases.
  • In the United States the Melphalan/Hepatic Delivery System is currently being investigated in a phase 3 trial in patients with metastatic ocular melanoma.
  • 1) Meijer, T.S., Burgmans, M.C., de Leede, E.M.et al.Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.Ann Surg Oncol(2020).
  • Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.Cardiovascular and interventional radiology,42(6), 841852. https://doi.org/10.1007/s00270-019-02177-x